Hemispherx Biopharma, Inc.
(NYSE Amex Equities : HEB)

( )
HEB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading HEB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.31%165.221.3%$782.35m
GILDGilead Sciences, Inc.
-0.06%67.061.0%$564.12m
INCYIncyte Corporation
0.02%139.514.3%$556.22m
CELGCelgene Corporation
0.00%124.431.1%$495.09m
BIIBBiogen Inc.
-0.44%272.901.3%$436.77m
REGNRegeneron Pharmaceuticals, Inc.
0.14%383.102.1%$349.89m
KITEKite Pharma, Inc.
0.00%78.6117.5%$217.46m
ALXNAlexion Pharmaceuticals, Inc.
0.00%118.531.6%$201.95m
TSROTESARO, Inc.
-0.58%154.0015.6%$192.28m
ILMNIllumina, Inc.
-0.47%170.003.4%$168.21m
VRTXVertex Pharmaceuticals Incorporated
19.85%107.472.0%$160.67m
ESPREsperion Therapeutics, Inc.
1.96%36.3617.7%$152.95m
CLVSClovis Oncology, Inc.
0.00%67.0617.2%$140.22m
AUPHAurinia Pharmaceuticals Inc.
0.70%7.218.0%$131.34m
EXELExelixis, Inc.
0.00%21.285.7%$104.55m

Company Profile

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.